SIGN UP

top stories

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

1 hour ago

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Yesterday

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

Yesterday

Notable shakeups this week; Recursion's mixed data; Eli Lilly's $1B bet; and more

Yesterday

Latest

Federal judge rejects pharma industry’s request to halt Maryland’s 340B law

Yesterday

Non-viral delivery startup Vesigen Therapeutics trims staff as it evaluates 'strategic options'

Yesterday

FDA grants full approval to Travere’s Filspari for IgAN

2 days ago

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

2 days ago

Milestone’s arrhythmia drug on track for China filing with new Phase 3 data

2 days ago

Basilea records $25M milestone; Connect Biopharma reduces workforce in China

2 days ago

see latest stream

People

Updated: Lykos CEO Amy Emerson resigns

3 days ago

IN8bio pauses glioblastoma program, halves workforce as it prioritizes leukemia asset

3 days ago

Dana-Farber chief Laurie Glimcher set to leave storied cancer center

4 days ago

Financing

Bicara, Zenas outline plans for $180M IPOs amid restored optimism for biotech debuts

2 days ago

Exclusive: Lilly-backed OrsoBio raises $67M for slate of obesity drugs as combinations take root

2 days ago

MDLive veterans nab $7.5M Series A for virtual specialty care startup

3 days ago

Startups

Exclusive: ZipBio launches using generative AI to make compact proteins

3 days ago

Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal

4 days ago

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

4 days ago

Deals

Court's ruling on Illumina-Grail deal could signal a limit to European antitrust powers

4 days ago

Novartis partners with small North Carolina biotech to make its biologics more 'convenient'

Last week

Bayer partners with RNA startup launched out of Dana-Farber

Last week

In FocusSee all

Recursion nears ‘moment of truth’ with first key data, kicking off 18-month flurry of readouts

Last week

Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal

Last week

The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders

Last month

A teenager faced constant seizures. Could a drug developed just for him stop them?

Last month

Endpoints Standouts

How the world's biggest pharma and biotech companies paid their typical worker in 2023

2 months ago

In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024

2 months ago

Biopharma leaders charting a path for the industry's LGBTQ+ community

2 months ago

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

2 months ago

Peer review See all

Sep

6

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Aug

30

J&J's human resources leader to retire; Amgen becomes the newest pharma with a top AI exec

Aug

23

Genmab makes two C-suite additions as COO leaves; James Sabry leads a revamped supporting cast at BioMarin

Aug

16

Esperion's CMO hits the exit; Pfizer appoints Nvidia alum as AI chief

Aug

9

Bill Haney's Dragonfly nabs former Cerevel CFO; Cellectis' new CMO

Pharma channel feed

2 days ago

FDA raises antimicrobial resistance concerns ahead of adcomm for Iterum's UTI treatment

The FDA has raised concerns about potential "inappropriate use" of Iterum’s oral candidate for uncomplicated urinary tract infections (uUTIs) ahead of a Monday advisory committee meeting.

READ MORE

J&J increases talc settlement by $1.1B after negotiating with plaintiffs, lawyers say

2 days ago

Ocaliva will continue to be available in the EU following European court's decision

2 days ago

latest in Pharma

Cigna offers discounted Stelara biosimilar, building on Humira move

2 days ago

BioMarin restructures following staff shakeup, slow Roctavian sales

3 days ago

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says

3 days ago

Moderna’s mpox vaccine outperforms approved version in preclinical study

3 days ago

Court orders J&J to pay $1B following buyout of surgical robotics company

3 days ago

see latest stories

Marketing channel feed

Last month

Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra

Madrigal Pharmaceuticals is “off to a strong start” with its recently approved MASH drug Rezdiffra, CEO Bill Sibold said on Wednesday. The company pulled $14.6 million in the first full ...

READ MORE

RSV market pressure leads to slower launch for Moderna's vaccine

Last month

Verona inks financing deal worth up to $650M ahead of COPD decision

4 months ago

latest in Marketing

From the editor: Our final edition of Endpoints MarketingRx

4 months ago

MarketingRx roundup: Moderna debuts social media science series; Boehringer expands NY mental health exhibit

4 months ago

Real Chemistry debuts a one-stop dashboard for all things GLP-1

4 months ago

Pharma reputation slips among patient advocacy groups, according to annual survey

4 months ago

Sanofi and Regeneron debut next generation in Dupixent's asthma campaign

4 months ago

see latest stories

FDA+ channel feed

2 days ago

CBER chief forecasts better global regulatory convergence around cell and gene therapies

Peter Marks, who's responsible for the FDA's oversight of cell and gene therapies, expects regulators around the world will be better at collaborating on gene therapy approvals within the ...

READ MORE

European Commission revokes Ocaliva's authorization ahead of FDA adcomm

4 days ago

FDA authorizes Novavax's updated Covid booster

Last week

latest in FDA+

Biosecure vote slated for September

Last week

Ipsen sells priority review voucher for highest price since 2016

Last week

FDA approves Emergent vaccine for mpox as company plans to donate 50,000 doses

Last week

FDA’s drug evaluation wing launches new AI oversight panel

Last week

Pennsylvania judge sides with drugmakers on first steps for growing GLP-1 lawsuits

Last week

see latest stories

Manufacturing channel feed

3 days ago

Astellas to close facility in California; Takeda can make more of its ADHD drug

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

READ MORE

With $200M investment, Novartis builds out radioligand manufacturing at two sites

3 days ago

Novo Nordisk continues to grapple with patchy GLP-1 drug supply in Europe

5 days ago

latest in Manufacturing

Corrected: Afrigen, CEPI to speed up mRNA vaccine manufacturing; Bora Pharma invests in Tanvex

Last week

Ahead of acquisition by Novo Holdings, are Catalent’s dark days behind it?

Last week

Sanofi pauses supply of two flu vaccines in China over ‘unexpected circumstances’

Last week

FDA warns EyePoint over eye implant manufacturing woes

Last week

Eli Lilly releases single-dose vials of Zepbound at half the price of other obesity meds

Last week

see latest stories